Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Equity to Asset 0.01
RDNT's Equity to Asset is ranked lower than
53% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. RDNT: 0.01 )
RDNT' s 10-Year Equity to Asset Range
Min: -0.85   Max: 0.01
Current: 0.01

-0.85
0.01
Interest Coverage 1.25
RDNT's Interest Coverage is ranked lower than
54% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 566.16 vs. RDNT: 1.25 )
RDNT' s 10-Year Interest Coverage Range
Min: 0.22   Max: 1.33
Current: 1.25

0.22
1.33
F-Score: 6
Z-Score: 1.23
M-Score: -2.84
WACC vs ROIC
7.27%
5.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.00
RDNT's Operating margin (%) is ranked higher than
79% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. RDNT: 6.00 )
RDNT' s 10-Year Operating margin (%) Range
Min: -28.06   Max: 16.68
Current: 6

-28.06
16.68
Net-margin (%) 1.27
RDNT's Net-margin (%) is ranked higher than
73% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. RDNT: 1.27 )
RDNT' s 10-Year Net-margin (%) Range
Min: -49.85   Max: 13.48
Current: 1.27

-49.85
13.48
ROE (%) 52.10
RDNT's ROE (%) is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. RDNT: 52.10 )
RDNT' s 10-Year ROE (%) Range
Min: 52.1   Max: 52.1
Current: 52.1

ROA (%) 1.25
RDNT's ROA (%) is ranked higher than
75% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. RDNT: 1.25 )
RDNT' s 10-Year ROA (%) Range
Min: -39.36   Max: 13.24
Current: 1.25

-39.36
13.24
ROC (Joel Greenblatt) (%) 14.08
RDNT's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. RDNT: 14.08 )
RDNT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -44.17   Max: 31.78
Current: 14.08

-44.17
31.78
Revenue Growth (3Y)(%) 3.30
RDNT's Revenue Growth (3Y)(%) is ranked higher than
67% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. RDNT: 3.30 )
RDNT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.1   Max: 25.5
Current: 3.3

1.1
25.5
EBITDA Growth (3Y)(%) -5.70
RDNT's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. RDNT: -5.70 )
RDNT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.7   Max: 169.2
Current: -5.7

-5.7
169.2
EPS Growth (3Y)(%) -46.00
RDNT's EPS Growth (3Y)(%) is ranked higher than
55% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. RDNT: -46.00 )
RDNT' s 10-Year EPS Growth (3Y)(%) Range
Min: -46   Max: 28.4
Current: -46

-46
28.4
» RDNT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RDNT Guru Trades in Q2 2014

Paul Tudor Jones 10,084 sh (New)
Jim Simons 798,900 sh (New)
» More
Q3 2014

RDNT Guru Trades in Q3 2014

Paul Tudor Jones Sold Out
Jim Simons 532,800 sh (-33.31%)
» More
Q4 2014

RDNT Guru Trades in Q4 2014

Jim Simons 337,200 sh (-36.71%)
» More
Q1 2015

RDNT Guru Trades in Q1 2015

Paul Tudor Jones 36,100 sh (New)
Jim Simons 321,800 sh (-4.57%)
» More
» Details

Insider Trades

Latest Guru Trades with RDNT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 35.10
RDNT's P/E(ttm) is ranked higher than
86% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 35.10 )
RDNT' s 10-Year P/E(ttm) Range
Min: 1.43   Max: 46.63
Current: 35.1

1.43
46.63
Forward P/E 10.04
RDNT's Forward P/E is ranked higher than
99% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 10.04 )
N/A
PE(NRI) 35.70
RDNT's PE(NRI) is ranked higher than
86% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 35.70 )
RDNT' s 10-Year PE(NRI) Range
Min: 1.44   Max: 47.37
Current: 35.7

1.44
47.37
P/B 67.80
RDNT's P/B is ranked lower than
53% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. RDNT: 67.80 )
RDNT' s 10-Year P/B Range
Min: 35.71   Max: 930
Current: 67.8

35.71
930
P/S 0.40
RDNT's P/S is ranked higher than
98% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. RDNT: 0.40 )
RDNT' s 10-Year P/S Range
Min: 0.07   Max: 1.07
Current: 0.4

0.07
1.07
PFCF 10.90
RDNT's PFCF is ranked higher than
97% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 10.90 )
RDNT' s 10-Year PFCF Range
Min: 0.61   Max: 209.67
Current: 10.9

0.61
209.67
POCF 3.68
RDNT's POCF is ranked higher than
99% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 3.68 )
RDNT' s 10-Year POCF Range
Min: 0.54   Max: 25.17
Current: 3.68

0.54
25.17
EV-to-EBIT 20.47
RDNT's EV-to-EBIT is ranked higher than
89% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 20.47 )
RDNT' s 10-Year EV-to-EBIT Range
Min: 11.4   Max: 37.2
Current: 20.47

11.4
37.2
PEG 51.00
RDNT's PEG is ranked higher than
89% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 51.00 )
RDNT' s 10-Year PEG Range
Min: 0.18   Max: 169.18
Current: 51

0.18
169.18
Shiller P/E 29.00
RDNT's Shiller P/E is ranked higher than
91% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. RDNT: 29.00 )
RDNT' s 10-Year Shiller P/E Range
Min: 9.44   Max: 51.5
Current: 29

9.44
51.5
Current Ratio 1.46
RDNT's Current Ratio is ranked higher than
54% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. RDNT: 1.46 )
RDNT' s 10-Year Current Ratio Range
Min: 0.15   Max: 1.72
Current: 1.46

0.15
1.72
Quick Ratio 1.46
RDNT's Quick Ratio is ranked higher than
59% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. RDNT: 1.46 )
RDNT' s 10-Year Quick Ratio Range
Min: 0.15   Max: 1.72
Current: 1.46

0.15
1.72
Days Sales Outstanding 76.63
RDNT's Days Sales Outstanding is ranked higher than
72% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. RDNT: 76.63 )
RDNT' s 10-Year Days Sales Outstanding Range
Min: 53.25   Max: 127.51
Current: 76.63

53.25
127.51

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.32
RDNT's Price/Median PS Value is ranked higher than
57% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. RDNT: 2.32 )
RDNT' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 5.38
Current: 2.32

0.36
5.38
Earnings Yield (Greenblatt) 4.90
RDNT's Earnings Yield (Greenblatt) is ranked higher than
89% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. RDNT: 4.90 )
RDNT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 8.8
Current: 4.9

2.7
8.8
Forward Rate of Return (Yacktman) -4.56
RDNT's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.27 vs. RDNT: -4.56 )
RDNT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.9   Max: 100.8
Current: -4.56

-5.9
100.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:PQIA.Germany,
RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Companys sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is highly competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
research Jun 12 2011 
research Jun 12 2011 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 
RadNet Inc. Reports Operating Results (10-Q) Aug 09 2010 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 22,200 Shares Sep 22 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 77,800 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 69,215 Shares Sep 21 2009 
RadNet Inc. (RDNT) Executive VP and CFO Mark Stolper sells 30,785 Shares Sep 18 2009 

More From Other Websites
RADNET, INC. Financials May 16 2015
10-Q for RadNet, Inc. May 13 2015
CORRECTION -- RadNet Reports First Quarter Financial Results and Adjusts Upwards 2015 Guidance... May 12 2015
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 12 2015
RADNET, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Q1 2015 RadNet Inc Earnings Release - Before Market Open May 11 2015
RadNet reports 1Q loss May 11 2015
RadNet reports 1Q loss May 11 2015
RadNet Reports First Quarter Financial Results and Adjusts Upwards 2015 Guidance Ranges May 11 2015
RadNet, Inc. Announces Date of Its First Quarter 2015 Financial Results Conference Call May 04 2015
10-K for RadNet, Inc. May 03 2015
RADNET, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... May 01 2015
RadNet Secures Additional $75 Million as Part of Its Existing Senior Secured Credit Facility Apr 30 2015
10-K/A for RadNet, Inc. Apr 26 2015
RadNet Adds Eight Prime Manhattan Locations to Imaging Center Holdings Apr 15 2015
RadNet Expands Its New York City Presence Through the Acquisition of New York Radiology Partners Apr 14 2015
The Zacks Analyst Blog Highlights: Caterpillar, Procter & Gamble, Horizon Pharma, RadNet and PRA... Apr 07 2015
Jobs Data Dips: 3 Healthy Picks - Analyst Blog Apr 06 2015
RadNet Surges On B. Riley Initiation Mar 26 2015
RADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK